p53和P-糖蛋白影响肝细胞癌的化疗耐药性。
p53 and P-glycoprotein influence chemoresistance in hepatocellular carcinoma.
作者信息
Li ShengLei, Gao Ming, Li ZongMing, Song LiJie, Gao XianZheng, Han Jing, Wang Feng, Chen YongFang, Li WenCai, Yang JianPing
机构信息
Department of Pathology, The First Affliated Hospital of ZhengZhou University, ZhengZhou, 450000, China.
Department of Oncology, The First Affliated Hospital of ZhengZhou University, ZhengZhou, 450000, China.
出版信息
Front Biosci (Elite Ed). 2018 Jun 1;10(3):461-468. doi: 10.2741/E833.
Chemoresistance is a critical obstacle to the treatment of hepatocellular carcinoma (HCC). The mechanisms underlying resistance to doxorubicin, cisplatin, and 5-fluorouracil involve p53 and P-glycoprotein (P-gp). p53 plays a role in cell growth; therefore, resistance mechanisms involve chemotherapy-induced apoptosis and p53 mutation and inactivation. P-gp is an energy-dependent drug efflux pump regulated by p53. Its role in drug resistance has provided new insights into the mechanisms underlying the involvement of p53 and P-gp in chemoresistance and may alter our traditional understanding of p53 and P-gp function. This review outlines the roles and principal mechanisms of p53 and P-gp mediated chemoresistance in HCC.
化疗耐药是肝细胞癌（HCC）治疗中的一个关键障碍。对阿霉素、顺铂和5-氟尿嘧啶耐药的潜在机制涉及p53和P-糖蛋白（P-gp）。p53在细胞生长中起作用；因此，耐药机制涉及化疗诱导的细胞凋亡以及p53突变和失活。P-gp是一种受p53调节的能量依赖性药物外排泵。其在耐药中的作用为p53和P-gp参与化疗耐药的潜在机制提供了新的见解，并可能改变我们对p53和P-gp功能的传统认识。本综述概述了p53和P-gp介导的HCC化疗耐药的作用和主要机制。
Zotero 插件